Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1966 3
1968 1
1969 1
1977 1
1978 1
1984 1
1990 2
1991 2
1993 6
1994 6
1995 7
1996 6
1997 9
1998 8
1999 15
2000 8
2001 8
2002 3
2003 2
2004 4
2005 2
2006 5
2007 2
2009 1
2010 2
2011 4
2012 11
2013 16
2014 12
2015 11
2016 14
2017 20
2018 20
2019 22
2020 25
2021 24
2022 15
2023 18
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

296 results

Results by year

Filters applied: . Clear all
Page 1
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M. Mato AR, et al. Among authors: ku nc. Lancet. 2021 Mar 6;397(10277):892-901. doi: 10.1016/S0140-6736(21)00224-5. Lancet. 2021. PMID: 33676628 Clinical Trial.
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Drilon A, et al. Among authors: ku nc. N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448. N Engl J Med. 2018. PMID: 29466156 Free PMC article. Clinical Trial.
Roles of Keratins in Intestine.
Mun J, Hur W, Ku NO. Mun J, et al. Among authors: ku no. Int J Mol Sci. 2022 Jul 21;23(14):8051. doi: 10.3390/ijms23148051. Int J Mol Sci. 2022. PMID: 35887395 Free PMC article. Review.
Interim Guidelines on Antiviral Therapy for COVID-19.
Kim SB, Huh K, Heo JY, Joo EJ, Kim YJ, Choi WS, Kim YJ, Seo YB, Yoon YK, Ku NS, Jeong SJ, Kim SH, Peck KR, Yeom JS. Kim SB, et al. Among authors: ku ns. Infect Chemother. 2020 Jun;52(2):281-304. doi: 10.3947/ic.2020.52.2.281. Epub 2020 Apr 23. Infect Chemother. 2020. PMID: 32342676 Free PMC article. Review.
The sweet side of vimentin.
Snider NT, Ku NO, Omary MB. Snider NT, et al. Among authors: ku no. Elife. 2018 Mar 7;7:e35336. doi: 10.7554/eLife.35336. Elife. 2018. PMID: 29513215 Free PMC article.
Keratins: guardians of the liver.
Omary MB, Ku NO, Toivola DM. Omary MB, et al. Among authors: ku no. Hepatology. 2002 Feb;35(2):251-7. doi: 10.1053/jhep.2002.31165. Hepatology. 2002. PMID: 11826396 Review. No abstract available.
Intermediate filaments of the lung.
Yi H, Ku NO. Yi H, et al. Among authors: ku no. Histochem Cell Biol. 2013 Jul;140(1):65-9. doi: 10.1007/s00418-013-1105-x. Epub 2013 Jun 14. Histochem Cell Biol. 2013. PMID: 23765163 Review.
Keratins: markers and modulators of liver disease.
Strnad P, Paschke S, Jang KH, Ku NO. Strnad P, et al. Among authors: ku no. Curr Opin Gastroenterol. 2012 May;28(3):209-16. doi: 10.1097/MOG.0b013e3283525cb8. Curr Opin Gastroenterol. 2012. PMID: 22450891 Review.
296 results